Healthy volunteers test First-in-Human drug for lung scarring
NCT ID NCT06267183
First seen Mar 15, 2026 · Last updated May 15, 2026 · Updated 12 times
Summary
This early-stage study tests a new drug, SV001, in 53 healthy Chinese adults to see if it is safe and how the body processes it. The drug is being developed for idiopathic pulmonary fibrosis, a serious lung-scarring disease. This trial does not involve patients with the disease and focuses only on safety and drug levels in healthy volunteers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Xuhui District Central Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.